返回
Primary hyperparathyroidism
DOI:10.1038/nrdp.2016.33.png)
摘要
En 中文
Primary hyperparathyroidism (PHPT) is a common disorder in which parathyroid hormone (PTH) is excessively secreted from one or more of the four parathyroid glands. A single benign parathyroid adenoma is the cause in most people. However, multiglandular disease is not rare and is typically seen in familial PHPT syndromes. The genetics of PHPT is usually monoclonal when a single gland is involved and polyclonal when multiglandular disease is present. The genes that have been implicated in PHPT include proto-oncogenes and tumour-suppressor genes. Hypercalcaemia is the biochemical hallmark of PHPT. Usually, the concentration of PTH is frankly increased but can remain within the normal range, which is abnormal in the setting of hypercalcaemia. Normocalcaemic PHPT, a variant in which the serum calcium level is persistently normal but PTH levels are increased in the absence of an obvious inciting stimulus, is now recognized. The clinical presentation of PHPT varies from asymptomatic disease (seen in countries where biochemical screening is routine) to classic symptomatic disease in which renal and/or skeletal complications are observed. Management guidelines have recently been revised to help the clinician to decide on the merits of a parathyroidectomy or a non-surgical course. This Primer covers these areas with particular attention to the epidemiology, clinical presentations, genetics, evaluation and guidelines for the management of PHPT.
Keyword:
ASYMPTOMATIC PRIMARY HYPERPARATHYROIDISM
QUALITY-OF-LIFE
ENDOCRINE NEOPLASIA TYPE-1
FAMILIAL HYPOCALCIURIC HYPERCALCEMIA
PARATHYROID-HORMONE GENE
CHRONIC-RENAL-FAILURE
GERM-LINE MUTATIONS
SERUM-CALCIUM
HRPT2 GENE
VITAMIN-D
AI总结
对已上传原文的论文进行重点信息的提取,主要内容包括:简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
N
IF:
60.6
论文数:
662
被引数:
4.8W
机构
引用论文
An N-terminal molecular form of parathyroid hormone (PTH) distinct from hPTH(1-84) is overproduced in parathyroid carcinoma
CLINICAL CHEMISTRY
IF6.3
PRIMARY HYPERPARATHYROIDISM IS ASSOCIATED WITH SUBCLINICAL PERIPHERAL NEURAL ALTERATIONS
ENDOCRINE PRACTICE
IF4.6

